IntelliPharmaCeutics International Inc.
) was a big mover last session, as the company saw its shares shoot
by nearly 162% on the day. The move came on solid volume too with
far more shares changing hands than in a normal session as the
company gained the U.S. Food and Drug Administration's approval to
market the generic version of attention deficit hyperactive
disorder drug, Focalin XR. The closing price represents a
substantial jump from the near-flat trading range of $1.68 to $2.00
in the past one-month time frame.
This biopharmaceutical company has seen no estimate revisions in
the past 30 days and its Zacks Consensus Estimate has remained
unchanged. Yesterday's price action is encouraging though, so make
sure to keep a close watch on this firm in the near future.
IntelliPharmaCeutics currently has a Zacks Rank #3 (Hold) and its
Some better performing stocks in the same industry include
Lannett Company, Inc.
Jazz Pharmaceuticals Public Limited Company
Furiex Pharmaceuticals, Inc.
). While Lannett and Jazz carry a Zacks Rank #1 (Strong Buy),
Furiex carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download
7 Best Stocks for the Next 30 Days
Click to get this free report >>
FURIEX PHARMACT (FURX): Free Stock Analysis
INTELLIPHARMACT (IPCI): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.